Aim: To assess the efficacy of Intracameral (bevacizumab) in combination with and without pan retinal photocoagulation (PRP) in regressing anterior chamber iris and angle neovascularization and stabilizing IOP and improving outcome of secondary neovascular glaucoma in patients with proliferative retinal ischemic disorders in our population. Methods: A Prospective, consecutive, interventional case series study was conducted at AFIO RWP and CMH Khuzdar on a series of patients 25 to 70 years of age. Thirty patients (30 eyes) with NVG secondary to ischemic retinal disorders were enrolled in the study design. The study group included 18(60%) males and 12 (40%) females. Cases were divided into two groups (A, B) and written informed consent was taken prior to procedure. Group A (15 patients) were managed with Intracameral bevacizumab alone While group B (15 patients) received laser pan retinal photocoagulation in addition to Intracameral bevacizumab. Majority had proliferative diabetic retinopathy (21 cases) and remaining nine cases were secondary to ischemic central retinal vein occlusion (CRVO). Baseline records were documented after carrying out complete ophthalmic evaluation in all patients. Follow up was carried out for 03 to 06 months depending on patient compliance. Results: Significantly better reduction of Iris (rubeosis) and anterior chamber angle neovascularization and stabilizing of IOP was observed in Group B who received PRP in addition to Intracameral bevacizumab as compared to group A who were managed with Intracameral bevacizumab alone. Moreover early remission of neovascularization was observed in group A receiving bevacizumab only. Conclusions: Combined procedures seems to be more effective in regressing and stabilizing iris/angle neovascularization, and lowering IOP in patients with NVG particularly in advanced cases.
|Number of pages||4|
|Journal||Pakistan Journal of Medical and Health Sciences|
|Publication status||Published - 1 Jan 2014|